SSA
LUMO

Schonfeld Strategic Advisors’s Lumos Pharma, Inc. Common Stock LUMO Stock Holding History

Schonfeld Strategic Advisors’s Portfolio LUMO Stock Details LUMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-2,722
Closed -$177K – 1014
2018
Q1 		$177K Buy
+2,722
New +$193K 0.01% 693
2017
Q2 		– Sell
-1,615
Closed -$351K – 804
2017
Q1 		$351K Buy
+1,615
New +$231K 0.04% 438

Other funds holding LUMO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Schonfeld Strategic Advisors's LUMO Position: Q2 2018 in Review

Schonfeld Strategic Advisors sold out of Lumos Pharma, Inc. Common Stock (LUMO) in Q2 2018, closing a stake of 2,722 shares — an estimated $177K sold.

Schonfeld Strategic Advisors first reported a position in LUMO in Q1 2017 and held it in 2 quarters. The position peaked at $351K in Q1 2017. 106 funds tracked by Wall St. Rank hold LUMO as of Q2 2018.

  • Schonfeld Strategic Advisors reported no remaining Lumos Pharma, Inc. Common Stock position as of Q2 2018 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 2,722 Lumos Pharma, Inc. Common Stock shares in Q2 2018, an estimated $177K.
  • Schonfeld Strategic Advisors first reported a position in Lumos Pharma, Inc. Common Stock in Q1 2017 and held it in 2 quarters.
  • Schonfeld Strategic Advisors's Lumos Pharma, Inc. Common Stock position peaked at $351K in Q1 2017.
  • 106 funds tracked by Wall St. Rank held Lumos Pharma, Inc. Common Stock as of Q2 2018.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2018, filed 14 Aug 2018.